Search results for "Migraine"
Prophylactic injectable monoclonal antibody reduced migraine days, industry trial finds
Compared with nonspecific oral drugs, patients treated with erenumab were six times more likely to achieve 50% or more reduction in monthly migraine days and were 11 times more likely to complete the treatment on the first attempt, authors reported.
https://immattersacp.org/weekly/archives/2024/04/02/4.htm
2 Apr 2024
MKSAP Quiz: 2-year history of migraine
A 20-year-old man is evaluated for a 2-year history of migraine that began when he started college. Migraine episodes occur 6 to 12 days per month, with more frequent episodes associated with increased stress from difficult assignments or final examinations. All physical examination findings, including vital signs, are unremarkable. What is the most appropriate preventive measure?
https://immattersacp.org/weekly/archives/2024/03/12/3.htm
12 Mar 2024
New 'weighs' to treat obesity
Even as the data on weight loss drugs mount, physicians need to help patients navigate potentially prohibitive costs and a continuing need for lifestyle change.
https://immattersacp.org/archives/2024/03/new-weighs-to-treat-obesity.htm
1 Mar 2024
MKSAP Quiz: 1-year history of widespread joint, muscle pain
A 37-year-old woman is evaluated for a 1-year history of widespread joint and muscle pain, fatigue, poor sleep, and difficulty focusing. Following a physical exam and lab tests, what is the most likely diagnosis?
https://immattersacp.org/weekly/archives/2024/01/09/3.htm
9 Jan 2024
Sorting out vertigo
A shift in diagnostic approach for vertigo involves asking about the timing and triggers for episodes rather than a description of symptoms.
https://immattersacp.org/archives/2024/01/sorting-out-vertigo.htm
1 Jan 2024
Tirzepatide for weight management, at-home STI tests
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2024/01/tirzepatide-for-weight-management-at-home-sti-tests.htm
1 Jan 2024
Ubrogepant appears effective for early acute treatment of migraine
An industry-funded trial found that ubrogepant was associated with absence of moderate or severe headache within 24 hours 46% of the time versus 29% with placebo when taken during the prodrome period (nonaura symptoms preceding headache onset).
https://immattersacp.org/weekly/archives/2023/11/21/2.htm
21 Nov 2023
Handling the hassle of administrative hurdles
CMS released a proposed rule to address the administrative hassles of prior authorizations in Medicare Advantage plans, calling for automated processes, shorter decision-making time frames, and more transparency about the services subject to prior authorizations.
https://immattersacp.org/archives/2023/11/handling-the-hassle-of-administrative-hurdles.htm
1 Nov 2023
RSV vaccine approved; several actions on opioids
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2023/06/rsv-vaccine-approved-several-actions-on-opioids.htm
1 Jun 2023
MKSAP Quiz: Increased frequency of long-term headaches
This week's quiz asks readers to determine the most appropriate next step in treatment for a 48-year-old man with a 25-year history of headaches that have become increasingly frequent.
https://immattersacp.org/weekly/archives/2023/04/18/3.htm
18 Apr 2023